Tags

Type your tag names separated by a space and hit enter

Cefotetan-Induced Hemolytic Anemia: Case Series and Review.
J Pharm Pract. 2019 Dec; 32(6):679-682.JP

Abstract

PURPOSE

To raise awareness of cefotetan-induced hemolytic anemia, a known rare but serious side effect that occurred in 5 patients at our medical center.

SUMMARY

Five cases of cefotetan-induced hemolytic anemia, which presented over the period of a single year at our center, are described. In each case, hemolytic anemia was confirmed by testing for the presence of anti-cefotetan antibodies. Each case occurred approximately 1 to 2 weeks following exposure to the drug. All five patients survived. A brief review of drug-induced immune hemolytic anemia (DIIHA) is also discussed.

CONCLUSION

DIIHA may be difficult to distinguish from other causes of hemolytic anemia, but should be included in the differential in patients exposed to medications associated with DIIHA. Once suspected, antibody testing should be performed, and once diagnosed, further exposure should be avoided.

Authors+Show Affiliations

Cedars Sinai Medical Center, Los Angeles, CA, USA.Department of Pharmacy, Cedars Sinai Medical Center, Los Angeles, CA, USA.Department of Pharmacy, Cedars Sinai Medical Center, Los Angeles, CA, USA.Center for Drug Policy, Partners Healthcare, Somerville, MA, USA.Department of Pharmacy, Cedars Sinai Medical Center, Los Angeles, CA, USA.Division of Transfusion Medicine, Department of Pathology, Cedars Sinai Medical Center, Los Angeles, CA, USA.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

30189781

Citation

Lim, Kathlyn, et al. "Cefotetan-Induced Hemolytic Anemia: Case Series and Review." Journal of Pharmacy Practice, vol. 32, no. 6, 2019, pp. 679-682.
Lim K, Tran H, Hirai-Yang A, et al. Cefotetan-Induced Hemolytic Anemia: Case Series and Review. J Pharm Pract. 2019;32(6):679-682.
Lim, K., Tran, H., Hirai-Yang, A., Vakil, N., Marks, G., & Klapper, E. (2019). Cefotetan-Induced Hemolytic Anemia: Case Series and Review. Journal of Pharmacy Practice, 32(6), 679-682. https://doi.org/10.1177/0897190018798198
Lim K, et al. Cefotetan-Induced Hemolytic Anemia: Case Series and Review. J Pharm Pract. 2019;32(6):679-682. PubMed PMID: 30189781.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cefotetan-Induced Hemolytic Anemia: Case Series and Review. AU - Lim,Kathlyn, AU - Tran,Hai, AU - Hirai-Yang,Angela, AU - Vakil,Niyati, AU - Marks,Gregory, AU - Klapper,Ellen, Y1 - 2018/09/06/ PY - 2018/9/8/pubmed PY - 2020/4/16/medline PY - 2018/9/8/entrez KW - cefotetan KW - cephalosporins KW - cephamycins KW - drug-induced hemolytic anemia KW - hemolytic anemia SP - 679 EP - 682 JF - Journal of pharmacy practice JO - J Pharm Pract VL - 32 IS - 6 N2 - PURPOSE: To raise awareness of cefotetan-induced hemolytic anemia, a known rare but serious side effect that occurred in 5 patients at our medical center. SUMMARY: Five cases of cefotetan-induced hemolytic anemia, which presented over the period of a single year at our center, are described. In each case, hemolytic anemia was confirmed by testing for the presence of anti-cefotetan antibodies. Each case occurred approximately 1 to 2 weeks following exposure to the drug. All five patients survived. A brief review of drug-induced immune hemolytic anemia (DIIHA) is also discussed. CONCLUSION: DIIHA may be difficult to distinguish from other causes of hemolytic anemia, but should be included in the differential in patients exposed to medications associated with DIIHA. Once suspected, antibody testing should be performed, and once diagnosed, further exposure should be avoided. SN - 1531-1937 UR - https://www.unboundmedicine.com/medline/citation/30189781/Cefotetan-Induced_Hemolytic_Anemia:_Case_Series_and_Review L2 - http://journals.sagepub.com/doi/full/10.1177/0897190018798198?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -